FP
EDIT icon

Financial Perspectives’s Editas Medicine EDIT Stock Holding History

Financial Perspectives’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19 Hold
6
– – ﹤0.01% 725
2026
Q1 		$15 Hold
6
– – ﹤0.01% 713
2025
Q4 		$12 Hold
6
– – ﹤0.01% 711
2025
Q3 		$21 Hold
6
– – ﹤0.01% 719
2025
Q2 		$13 Hold
6
– – ﹤0.01% 721
2025
Q1 		$7 Hold
6
– – ﹤0.01% 723
2024
Q4 		$8 Hold
6
– – ﹤0.01% 726
2024
Q3 		$20 Hold
6
– – ﹤0.01% 684
2024
Q2 		$28 Hold
6
– – ﹤0.01% 678
2024
Q1 		$45 Hold
6
– – ﹤0.01% 661
2023
Q4 		$61 Hold
6
– – ﹤0.01% 693
2023
Q3 		$47 Hold
6
– – ﹤0.01% 695
2023
Q2 		$49 Hold
6
– – ﹤0.01% 676
2023
Q1 		$44 Hold
6
– – ﹤0.01% 676
2022
Q4 		$53 Hold
6
– – ﹤0.01% 679
2022
Q3 		$73 Hold
6
– – ﹤0.01% 689
2022
Q2 		$71 Hold
6
– – ﹤0.01% 688
2022
Q1 		$114 Hold
6
– – ﹤0.01% 681
2021
Q4 		$159 Hold
6
– – ﹤0.01% 643
2021
Q3 		$246 Hold
6
– – ﹤0.01% 632
2021
Q2 		$340 Hold
6
– – ﹤0.01% 644
2021
Q1 		$252 Buy
+6
New +$342 ﹤0.01% 618

Other funds holding EDIT

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Financial Perspectives's EDIT Position: Q2 2026 in Review

Financial Perspectives held its Editas Medicine (EDIT) position steady in Q2 2026 at 6 shares worth $19. The position accounts for ﹤0.01% of the portfolio, ranked #725.

Financial Perspectives first reported a position in EDIT in Q1 2021 and has held it in 22 quarters since. The position peaked at $340 in Q2 2021. 216 funds tracked by Wall St. Rank hold EDIT as of Q2 2026.

  • Financial Perspectives held 6 shares of Editas Medicine worth $19 as of Q2 2026.
  • Financial Perspectives left its Editas Medicine share count unchanged in Q2 2026.
  • Editas Medicine made up ﹤0.01% of Financial Perspectives's portfolio in Q2 2026, its #725 holding.
  • Financial Perspectives first reported a position in Editas Medicine in Q1 2021 and has held it in 22 quarters since.
  • Financial Perspectives's Editas Medicine position peaked at $340 in Q2 2021.
  • 216 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2026.

Based on Financial Perspectives's 13F filing for Q2 2026, filed 24 Jul 2026.